Meridian Bioscience Initiates Clinical Trials

Meridian Bioscience Initiates Clinical Trials

Meridian Bioscience said Wednesday it initiated clinical trials for an illumigene congenital Cytomegalovirus (CMV) molecular amplification test, after enrolling an international team of global experts in neonatal CMV infections to support the studies. Shares drifted marginally higher intraday. The assay is designed to specifically detect the CMV infection in newborns from saliva, the company said in a statement. Presently, there is no Food and Drugs Administration-cleared test for CMV screening […]

Read More ˃